Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia

Endocrine Research

Volumn 37, Issue 1, 2012, Pages 1-6

  Meléndez Ramrez, Gabriela ^a   Pérez Méndez, Oscar ^a   López Osorio, Cristhel ^a   Kuri Alfaro, Jorge ^a   Espinola Zavaleta, Nilda ^a  

^a Instituto Nacional de Cardiologa Ignacio Chávez   (Mexico)

Author keywords

Allopurinol; Brachial artery; Endothelial dysfunction; Flow mediated vasodilation; Hyperuricemia

Indexed keywords

ALLOPURINOL; URIC ACID;

ADULT; ARTICLE; BLOOD FLOW; BRACHIAL ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK FACTOR; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ALLOPURINOL; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; URIC ACID; VASODILATION;

EID: 84255193010     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2011.566235     Document Type: Article

References (19)

1. Endemann D, Schiffrin E. Endothelial dysfunction. J AmSocNephrol 2004;15:1983-1992. (Pubitemid 39031337)
2. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109(suppl. II):II-27-II-33.
3. Giordano F. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500-508. (Pubitemid 40322219)
4. Fenster B, Tsao P, Rockson S. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003;146:218-226. (Pubitemid 36951764)
5. Lin Sh, Tsai D, Hsu Sh. Association between serumuric acid level and components of the metabolic syndrome. J Chin Med Assoc 2006;69(11):512-516. (Pubitemid 46017171)
6. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951-1957.
7. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-1997. (Pubitemid 36506072)
8. Hoieggen A, Alderman M, Kjeldsen S, et al. Life Study Group: the impact of uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-1049. (Pubitemid 38251080)
9. Berry CE,Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecularmechanism and pathophysiological implications. J Physiol 2004;555:589-606. (Pubitemid 38404582)
10. DoehnerW, Schoene N, Rauchhaus M, Leyva-Leon F, PavittD. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure results from 2 placebo-controlled studies. Circulation 2002;105:2619-2624. (Pubitemid 34596038)
11. George J, Carr E, Davies J, Belch J, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-2516. (Pubitemid 44901524)
12. Balletshofer B, Rittig K, Enderle M, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000;101:1780-1784. (Pubitemid 30213098)
13. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr., Lerman A. Long term follow up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101: 948-954. (Pubitemid 30131694)
14. Frick M, Suessenbacher A, Albert HF, et al. Prognostic value of brachial artery endothelial function and wall thickness. J Am Coll Cardiol 2005;46:1006-1010. (Pubitemid 41316507)
15. Correti MC, Anferson TJ, Benjamn EJ, et al. Guidelines for ultrasound assessment of endothelialdependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002;39:257-265.
16. OstadMA, Eggeling S, Tschentscher P, et al. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 2009;205:227-232.
17. Tsutsumi Z, Moriwaki Y, Takahashi S, Ka T, Yamamoto T. Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta 2004;339:117-122. (Pubitemid 37547948)
18. Baker JF, Krishnan E, Chen L, Schumancher HR. Serumuric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-826. (Pubitemid 41097455)
19. Masahiko K, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilatation in patients with hyperuricemia. Am J Cardiol 2005;96:1576-1578. (Pubitemid 41690182)